Antimicotic sensibility tests in clinical isolates of Candida spp of cancer patients
Keywords:
Microbial sensitivity test, Candida, isolation and purification, neoplasms, yeast, antifungal agentsAbstract
Objective: To determine the antimicotic susceptibility of Candida spp isolates obtained from oncologic patients with one or more episodes of infection and to establish the susceptibillity and resistance profiles to the different antimicotics.
Materials and methods: The broth microdilution reference method (NCCLS, document M27-A) was employed to determine the in vitro susceptibility to amphotericin B, fluconazole, itraconazole, and ketoconazole in 181 isolates recovered between 1999 and 2002 from 67 cancer patients.
Results: C. albicans was the more frequent etiologic agent isolated (51,6%, 95/181), followed by C. tropicalis (34,2%, 62/181). 15,2% of the isolates showed resistance to amphotericin B (CMI > 1 µg/mL) and 19,6% showed resistance to fluconazole. There were no differences in susceptibility between C. albicans isolates and non-albicans Candida species. The C. glabrata isolates showed higher resistance to amphotericin B than and other Candida isolates (p = 0.006).
Discussion: The observed frequencies for C. albicans and non-albicans Candida species were similar to the frequencies reported for oncologic patients in other studies. The observed resistance to amphotericin B was higher than the one reported in other works, so that additional confirmatory studies are required. It was not possible to compare the sensibility prevalence to azoles, due to the absence of similar studies. In vitro susceptibility test and species identification are important tools at clinic and epidemiologic levels to detect potentially resistant Candida spp. strains.
Author Biography
Pilar Rivas, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología E.S.E., Laboratorio Clínico Bogotá, D. C., Colombia.
References
Berrouane YF, Herwaldt LA, Pfalter MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999 Mar;32(2):531-7. https://doi.org/10.1128/JCM.37.3.531-537.1999
Pfalter MA, Jones RN, Doem GV, Sender HS, Messer SA, Huoston A, Coffman SM, et al. Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance program in North America and Latin America, 1997-98. Antimicrob Agents Chemother 2000 Mar;44(3):747-51. https://doi.org/10.1128/AAC.44.3.747-751.2000
Sheeman DJ, Hitchcock CA, Sibley CM. Current and emerging azoles antifungal agents. Clin Microbiol Rev 1999 Jan;12(1 ):40-79. https://doi.org/10.1128/CMR.12.1.40
Boken DJ, Swindells S, Rinald MG. Fluconazoleresistant Candida albicans. Clin Infect Dis 1993; 7(6): 1018-21. https://doi.org/10.1093/clinids/17.6.1018
Bodey GR Candidiasis: Pathogenesis, diagnosis, and treatment. New York: Raven Press; 1993.
Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25. https://doi.org/10.1093/clinids/20.1.115
National Committee for Clinical Laboratory Stan dard. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27A. Villanova, PA: National Committee for Clinical Laboratory Standards; 1997.
Espinel-Ingroff A. Fungal identification and antifungal susceptibility testing. Workshop 1997Jul 21-25, Universidad de los Andes, Bogotá (Colombia). https://doi.org/10.1016/0196-4399(96)88204-3
Galgiani JN, Batlett M, Espinel A, Fromtling R, Pfaller M, Rinaldi M. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Proposed Standard. NCCLS Document M 27- PA (1SB1-56238-186-5). Villanova, PA: National Committee for Clinical Laboratory Standards. 1992;12(25):l-25.
Pfaller MA, Yu WL. Antifungal susceptibility testing. New technology and clinical applications. Infect Dis Clin North Am 2001 Dec;15(4):1227-61. https://doi.org/10.1016/S0891-5520(05)70192-6
Rodríguez- Tudela JL, Rodero L, Cordoba S, Cuenca M. "Determination de la resistencia a los antifungicos en el laboratorio Memorias del 3°. Curso Hispano-Argentino de Micología Médica. 2000 Ag 28 - Sep 1; Buenos Aires (Argentina).
Perea M, Rodriguez S, Espinel IA, Sussmann PO, Cepero MC. Determinación de la sensibilidad e aislamientos clínicos de Candida spp de pacientes con cáncer frente a diferentes antimicóticos "Informe preliminar " [tesis de grado]. Santa Fé de Bogotá: Universidad de los Andes; 1997.
RexJH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev 2001 Oct;14:643-58. https://doi.org/10.1128/CMR.14.4.643-658.2001
Wong-Beringera A, Hindler J, Brankovic L, MuehlbauerL, Steele-Moore L. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients. Diagn Microbiol Infect Dis 2001 Jan;39(l):5-31. https://doi.org/10.1016/S0732-8893(00)00209-1
Pfaller MA, Rex JH. Antifungal susceptibility testing: Technical advances and potential clinical applications. Clin Infect Dis 1997;24:776-84. https://doi.org/10.1093/clinids/24.5.776
Rex JH, Pfaller MA, Galgiani JN, Baartlett M, Espinel IA, Ghannoum M, et al. Development of interpretive and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997 Jun;24(6):235-48. https://doi.org/10.1093/clinids/24.2.235
Ghannoum MA, RexJH, Galgiani JN. Minireview. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinic outcome. J Clinic Microbiol 1996;34(3):489-95. https://doi.org/10.1128/JCM.34.3.489-495.1996
Espinel-Ingroff A. Antifungal susceptibility testing. Clin Microbiol Newslitter 1996; 18(21): 161-8. https://doi.org/10.1016/0196-4399(96)88204-3
Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002 Oct 15;35(8):982-9. https://doi.org/10.1086/342384
Rodriguez-Tudela JL, Martinez J, DrondaF. Correlation of in-vitro susceptibility test results with clinical response: A study of azole therapy in AIDS patients. J Antimicrobiol Chemother 1995;35(6): 793-804. https://doi.org/10.1093/jac/35.6.793
Ascioglu S, De Pauw B, Bennett JE, et al. Analysis of Definitions Used In Clinical Research on Invasive Fungal Infections (IFI): Postal for New, Standardized Definitions. Poster presented at 39th ICAAC in San Francisco. Poster number 1639 in session 159 - Management of Fungal Infections in Humans. San Francisco; 1999.
Rex JH, Nelson PW, Paetznick UL, et al. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrobial Agents and Chemothera py 1998 Jan; 42(1): 129-34. https://doi.org/10.1128/AAC.42.1.129
Pfaller MA, Messer SS, Coffman S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations, by using broth microdilution methods to test five antifungal agents, including the new triazole DO870. J Clin Microbiol 1995 May ;33(5):1094-97. https://doi.org/10.1128/JCM.33.5.1094-1097.1995
Rodriguez-Tudela JL, Cuenca-Estrella M, Diaz-Guerra TM, Mellano M. Standarization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol 2001 July;39(7): 2513-7. https://doi.org/10.1128/JCM.39.7.2513-2517.2001
Rex JH, Chester R, Cooper JR, Merz WG, Galgiani JN, Anaissie EJ. Detection of ámphotericin Bresistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995 Apr;39(4); 906-9. https://doi.org/10.1128/AAC.39.4.906
Lozano-Chiu M, Nelson PW, Lancaster M, Pfaller MA, Rex JH. Lot-to-lot variability of Candida isolates to amphotericin B. J Clin Microbiol 1997 Jan; 35(l);270-2. https://doi.org/10.1128/JCM.35.1.270-272.1997
White TC, MarrKA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402. https://doi.org/10.1128/CMR.11.2.382
Dick JD, Rosengard BR, Merz WG. Incidence of poliene-resistant yeasts recovered for clinical specimens. Antimicrob Agents Chemother 1980; 18:158-163. https://doi.org/10.1128/AAC.18.1.158
Nolte FS, Parkinson T, Falconer DJ. Isolation and characterization of fluconazole and amphotericin B-resistant Candida albicans from blood of Wo patients with leukemia. Antimicrob Agents Chemo ther 1997 Jan;44( 1);196-99. https://doi.org/10.1128/AAC.41.1.196
Bart-Delabesse E, Deventer HV. Contribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a bum care unit. J Clin Microbiol 1995 Dec; 33(12):3278-83. https://doi.org/10.1128/JCM.33.12.3278-3283.1995
Redding SW, Pfaller MA. Variations in fluconazole susceptibility and DNA subtiping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one o more episodes of infections. J Clin Microbiol 1997 July, 35(7); 1 761-5. https://doi.org/10.1128/JCM.35.7.1761-1765.1997
Bart-Delabesse E. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazol. J Clinical Microbiol 1993 Nov ;31(11 );2933-7. https://doi.org/10.1128/JCM.31.11.2933-2937.1993
Denning DW, Baily GG, Hood SV. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 1997;16(4):261-80. https://doi.org/10.1007/BF01695630
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
